Zevra Therapeutics, Inc. (ZVRA) stock
ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.40+0.15 (+1.62%)
Close on Nov 17, 2026Market cap $558.21MP/E 10.1Yield –
Zevra Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Zevra Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was 60.5%. For fiscal 2025 it was -59.1%, against -368.5% the year before. The highest annual figure on record is 27.0% in fiscal 2021.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -59.1% | +309.4 |
| FY2024 | Dec 31, 2024 | -368.5% | −187.8 |
| FY2023 | Dec 31, 2023 | -180.6% | +238.3 |
| FY2022 | Dec 31, 2022 | -418.9% | −445.9 |
| FY2021 | Dec 31, 2021 | 27.0% | +69.2 |
| FY2020 | Dec 31, 2020 | -42.2% | +116.2 |
| FY2019 | Dec 31, 2019 | -158.4% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 42.3% | +316.8 |
| Q1 FY2026 | Mar 31, 2026 | 144.0% | +170.3 |
| Q4 FY2025 | Dec 31, 2025 | 27.3% | +155.3 |
| Q3 FY2025 | Sep 30, 2025 | 15.9% | +754.9 |
| Q2 FY2025 | Jun 30, 2025 | -274.5% | +260.4 |
| Q1 FY2025 | Mar 31, 2025 | -26.3% | +571.8 |
| Q4 FY2024 | Dec 31, 2024 | -128.0% | −10.7 |
| Q3 FY2024 | Sep 30, 2024 | -739.0% | −208.3 |
| Q2 FY2024 | Jun 30, 2024 | -534.8% | −461.0 |
| Q1 FY2024 | Mar 31, 2024 | -598.1% | −194.1 |
| Q4 FY2023 | Dec 31, 2023 | -117.3% | +343.3 |
| Q3 FY2023 | Sep 30, 2023 | -530.7% | −300.2 |
| Q2 FY2023 | Jun 30, 2023 | -73.8% | +1831.3 |
| Q1 FY2023 | Mar 31, 2023 | -404.0% | −357.1 |
| Q4 FY2022 | Dec 31, 2022 | -460.6% | −350.5 |
| Q3 FY2022 | Sep 30, 2022 | -230.5% | −117.5 |
| Q2 FY2022 | Jun 30, 2022 | -1905.2% | −1953.8 |
| Q1 FY2022 | Mar 31, 2022 | -46.9% | −104.3 |
| Q4 FY2021 | Dec 31, 2021 | -110.1% | +25.8 |
| Q3 FY2021 | Sep 30, 2021 | -113.1% | −50.1 |
| Q2 FY2021 | Jun 30, 2021 | 48.7% | +11.1 |
| Q1 FY2021 | Mar 31, 2021 | 57.4% | +238.1 |
| Q4 FY2020 | Dec 31, 2020 | -135.8% | +184.7 |
| Q3 FY2020 | Sep 30, 2020 | -63.0% | −91.2 |
| Q2 FY2020 | Jun 30, 2020 | 37.5% | – |
| Q1 FY2020 | Mar 31, 2020 | -180.7% | – |
| Q4 FY2019 | Dec 31, 2019 | -320.5% | – |
| Q3 FY2019 | Sep 30, 2019 | 28.2% | – |
See a number that looks wrong?